Pharmafile Logo
Pharmafocus logo
Advanced Search

Cancer

Showing 15 posts of 1067 posts found.

Old anti-drinking drug shows potential as cancer treatment

December 7, 2017
Research and Development Cancer, biotech, drugs, oncology, pharma, pharmaceutical

Disulfiram has been known as an anti-drinking compound for nearly seven decades. Initially, the compound was used in the vulcanisation …

News
fdaoutsideweb

Mylan’s Ogivri becomes first and only FDA-approved Herceptin biosimilar

December 4, 2017
Sales and Marketing Biocon, Cancer, FDA, Herceptin, Mylan, Roche, biosimilar, pharma

The FDA has announced the approval of Mylan’s Ogivri (trastuzumab-dkst), the first biosimilar version of Roche’s Herceptin to be authorised …

News
mr058666-web

Merck KGaA and Pfizer’s Bavencio fails at Phase 3 in gastric cancer

November 28, 2017
Research and Development Bavencio, Cancer, Merck, Pfizer, pharma

Merck KGaA and Pfizer have been rocked by the news that their jointly-developed anti-PD-L1 antibody failed to meet its primary …

News

NICE refuses Eisai’s breast cancer drug in new indication

November 28, 2017
Manufacturing and Production, Sales and Marketing Cancer, Eisai, Halaven, NICE, breast cancer, pharma

NICE has announced that it has rejected Eisai’s Halaven (eribulin) through draft guidance advising not to use the drug in …

News
shutterstock_187433765

Obesity leads to larger, harder-to-detect tumours in breast cancer, study finds

November 21, 2017
Manufacturing and Production, Research and Development Cancer, breast cancer, pharma

A study from Sweden’s Karolinska Institute has indicated that cancerous tumours in overweight women are likely to be larger and …

News

Roche unveils strong combination treatment data in lung cancer

November 20, 2017
Research and Development, Sales and Marketing Cancer, NSCLC< lung cancer, Roche, avastin, immunotherapy, pharma, tecentriq

Roche has unveiled new Phase 3 efficacy data which showed strong findings for its immunotherapy Tecentriq (atezolizumab) in combination with …

News
pfizer-building-logo1web

FDA expands use of Pfizer’s Sutent in kidney cancer

November 17, 2017
Medical Communications, Sales and Marketing Cancer, Kidney cancer, Pfizer, Sutent, pharma

Pfizer has announced that the FDA has expanded the use of its tyrosine kinase inhibitor Sutent (sunitinib malate) to include …

News
shutterstock_187433765

Breast cancer recurrence can occur up to 20 years after treatment, report shows

November 10, 2017
Medical Communications, Research and Development Cancer, breast cancer, pharma, tamoxifen

New findings from the Early Breast Cancer Trialists’ Collaborative Group have demonstrated that oestrogen receptor-positive (ER-positive) breast cancer is able …

News
nhs_sign

NHS England seals access deals with big pharma for breast cancer and MS

November 9, 2017
Sales and Marketing Cancer, Mavenclad, Merck, NHS, NHS England, NICE, Perjeta, Roche, Simon Stevens, breast cancer, multiple sclerosis

NHS England has entered into a commercial agreement with Merck which aims to provide access to innovative treatments for both …

News
shutterstock_206748499

17,000 English patients are surviving Stage 4 cancer for two years or more, new data shows

November 8, 2017
Research and Development Cancer, bladder cancer, breast cancer, colon cancer, lung cancer, pharma, prostate cancer

At least 17,000 people in the UK are living with Stage 4 cancer and have survived for two years or …

News
novartis_outside_1

Novartis’ Kisqali smashes Phase 3 primary endpoint in breast cancer for second time

November 8, 2017
Research and Development Cancer, Kisqali, Novartis, breast cancer, pharma

Novartis has revealed that its immunotherapy drug Kisqali (ribociclib) met its primary endpoint of progression-free survival in its second Phase …

News
roche_dark_0

FDA expands Roche drug indication to approve first-ever treatment for rare blood cancer

November 7, 2017
Manufacturing and Production, Sales and Marketing Cancer, Erdheim-Chester Disease, FDA, Roche, blood cancer, pharma

The FDA has announced the approval of Roche’s Zelboraf (vemurafenib) in the treatment of Erdheim-Chester Disease (ECD), expanding its already …

News
gsk_boronia_australia

GSK’s experimental multiple myeloma scores Breakthrough designation with FDA

November 3, 2017
Medical Communications, Research and Development, Sales and Marketing Cancer, FDA, GSK, GlaxoSmithKline, multiple myeloma, pharma

GlaxoSmithKline is celebrating the FDA’s decision to award its experimental therapy GSK2857916 with Breakthrough Therapy Designation as a monotherapy in …

News
dna-1903319_960_720

Small number of mutations driving most cancers

October 20, 2017
Medical Communications, Research and Development Cancer, biotech, drugs, pharma, pharmaceutical

Research from scientists at the Wellcome Trust Sanger Institute has found that only between one and 10 genetic mutations are …

News
portraits-1474_approved_cut

Access to Innovation: Beyond a ‘pharma-only’ approach

October 19, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, ecco, oncology

Peter Naredi, of ECCO, explores how a multi-dimensional approach is necessary to ensure that patients receive access to the most …

Feature
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026